Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Registration Number
- NCT00331851
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 584
Inclusion Criteria
- Type 2 diabetes
- Treatment with oral anti-diabetic drugs for at least 3 months
- HbA1c: 7.5-10.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.) in subjects on OAD combination therapy.
- Body Mass Index (BMI) less than or equal to 45 kg/m2
Exclusion Criteria
- Treatment with insulin within the last 3 months
- Treatment with any drug that could interfere with the glucose level
- Any serious medical condition
- Females who are pregnant, have intention of becoming pregnant or are breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HbA1c after 26 weeks of treatment
- Secondary Outcome Measures
Name Time Method Glycaemic control Safety and tolerability Beta-cell function body weight
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇬🇧Watford, United Kingdom
Novo Nordisk Investigational Site🇬🇧Watford, United Kingdom